Basic Inhalant Allergy Panel

The Basic Inhalant Allergy Panel is a blood test that measures allergen-specific IgE antibodies to 45 components from common airborne allergens. It provides a focused assessment of frequent indoor and outdoor triggers, including grass, tree and weed pollens, house dust mites, cat and dog allergens, and a CCD marker that may be relevant when interpreting cross-reactive IgE findings.

The panel may be considered when symptoms repeatedly appear during a particular pollen season, in dusty indoor environments, in specific homes or workplaces, or after contact with cats or dogs. Relevant patterns may include sneezing, a runny or blocked nose, itchy, red and watery eyes, or recurring coughing, wheezing and shortness of breath.

When a basic inhalant panel may be appropriate

This panel is intended as a focused first assessment when the clinical pattern suggests that common inhaled allergens could be contributing to symptoms. It may be useful for people with seasonal rhinitis or conjunctivitis, symptoms that recur around pets or household dust, or respiratory complaints that consistently worsen after a recognizable environmental exposure.

A basic panel may be sufficient when the suspected triggers fall within the common allergen groups included in the test. A broader inhalant panel or additional targeted testing may be considered when exposures are more complex, several environments appear to cause symptoms, occupational allergens are suspected, or the basic panel does not explain a convincing clinical pattern.

The test should not be used as unrestricted screening in people without relevant symptoms. Testing is most informative when the selected allergens reflect the patient’s medical history, environment, seasonality and suspected exposures.

Sensitization is not the same as clinical allergy

A positive specific IgE result means that the immune system has produced IgE antibodies against a tested allergen component. This is called sensitization. Sensitization does not automatically mean that exposure causes symptoms or that a clinically relevant allergy has been confirmed.

Clinical relevance depends on whether symptoms appear after actual exposure to the corresponding allergen. For pollen findings, the timing should be compared with local pollen seasons and the months when symptoms occur. For mites or animal allergens, the result should be considered alongside exposure at home, work, school or other regularly visited environments.

A positive result without a matching exposure and symptom pattern may not explain the patient’s complaints. A negative result also does not exclude every possible allergy, because the relevant allergen may not be included in the panel or the symptoms may have a non-allergic cause. Interpretation should therefore combine the report with the clinical history and, when needed, further medical evaluation.

What the panel examines

• 45 allergenic extracts and molecular components from common inhaled allergen groups
• Grass, tree and weed pollen components associated with seasonal exposure
• House dust mite components associated with year-round indoor exposure
• Cat and dog allergen components
• A CCD marker that may support interpretation of certain cross-reactive IgE patterns

The component-based format can provide more detailed information than a result that identifies only a broad allergen source. The clinical meaning of each detected component still depends on the person’s symptoms and exposure history.

How the test is performed

Step 1: Review the symptom and exposure pattern

Before testing, it is useful to note when symptoms began, whether they are seasonal or present throughout the year, and whether they become worse around dust, animals, outdoor vegetation or a particular building. Previous allergy reports, respiratory findings and a current medication list can provide additional context.

Step 2: Blood sample collection

A blood sample is collected through routine venipuncture. No allergen is applied to the skin, and the test does not require a controlled allergic reaction on the body.

Step 3: Laboratory measurement

The sample is analyzed for specific IgE antibodies against the 45 components included in the panel. The report presents the measured findings for the tested allergens and includes an interpretation.

Step 4: Clinical correlation

The results are compared with symptom timing, seasonality and real exposure. This step helps distinguish findings that plausibly explain symptoms from sensitizations that may not be clinically relevant.

Step 5: Planning the next step

Depending on the symptoms and findings, the next step may involve an allergy consultation, environmental exposure review, respiratory function testing, an eye or ear, nose and throat assessment, or additional targeted allergy testing. Medication changes or extensive allergen avoidance should not be based on the laboratory result alone.

Preparation and practical information

Fasting is not required. Antihistamines and corticosteroids generally do not need to be stopped for this blood-based test. Patients should nevertheless provide an up-to-date medication list and follow any individual instructions received before blood collection.

Before sending an inquiry through ZagrebMed, prepare a short description of the symptoms, the months or environments in which they occur, relevant pet and household exposures, previous allergy tests and any existing respiratory or specialist reports. This information can help clarify whether the basic panel is a suitable first test or whether a different diagnostic pathway should be discussed.